266 related articles for article (PubMed ID: 16752306)
1. Histone post-translational modification: from discovery to the clinic.
Thomas NR
IDrugs; 2006 Jun; 9(6):398-401. PubMed ID: 16752306
[No Abstract] [Full Text] [Related]
2. Histone modification enzymes: novel targets for cancer drugs.
Kristeleit R; Stimson L; Workman P; Aherne W
Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
4. Histone acetylation and methylation: combinatorial players for transcriptional regulation.
An W
Subcell Biochem; 2007; 41():351-69. PubMed ID: 17484136
[TBL] [Abstract][Full Text] [Related]
5. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
6. Histone modifying enzymes and cancer: going beyond histones.
Zhang K; Dent SY
J Cell Biochem; 2005 Dec; 96(6):1137-48. PubMed ID: 16173079
[TBL] [Abstract][Full Text] [Related]
7. Histone acetylation in gene regulation.
Verdone L; Agricola E; Caserta M; Di Mauro E
Brief Funct Genomic Proteomic; 2006 Sep; 5(3):209-21. PubMed ID: 16877467
[TBL] [Abstract][Full Text] [Related]
8. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
Yang XJ; Seto E
Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
[TBL] [Abstract][Full Text] [Related]
9. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
10. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
11. Abnormal histone modification patterns in lupus CD4+ T cells.
Hu N; Qiu X; Luo Y; Yuan J; Li Y; Lei W; Zhang G; Zhou Y; Su Y; Lu Q
J Rheumatol; 2008 May; 35(5):804-10. PubMed ID: 18398941
[TBL] [Abstract][Full Text] [Related]
12. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
13. [Histone acetylation, gene regulation and depression].
Vialou V
Med Sci (Paris); 2010 May; 26(5):465-7. PubMed ID: 20510142
[No Abstract] [Full Text] [Related]
14. [Biological diversity of protein lysine acetylation which has been revealed by small molecule inhibitors].
Shimazu T; Horinouchi S; Yoshida M
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1751-7. PubMed ID: 18051411
[No Abstract] [Full Text] [Related]
15. SnapShot: Histone-modifying enzymes.
Kouzarides T
Cell; 2007 Nov; 131(4):822. PubMed ID: 18022374
[No Abstract] [Full Text] [Related]
16. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.
Sun WJ; Zhou X; Zheng JH; Lu MD; Nie JY; Yang XJ; Zheng ZQ
Acta Biochim Biophys Sin (Shanghai); 2012 Jan; 44(1):80-91. PubMed ID: 22194016
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
Delarue FL; Adnane J; Joshi B; Blaskovich MA; Wang DA; Hawker J; Bizouarn F; Ohkanda J; Zhu K; Hamilton AD; Chellappan S; Sebti SM
Oncogene; 2007 Feb; 26(5):633-40. PubMed ID: 16909123
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors as anti-neoplastic agents.
Batty N; Malouf GG; Issa JP
Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
[TBL] [Abstract][Full Text] [Related]
19. Promises and challenges of anticancer drugs that target the epigenome.
Verbrugge I; Johnstone RW; Bots M
Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
[TBL] [Abstract][Full Text] [Related]
20. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
